Landscape Capital Management L.L.C. Purchases New Stake in Neuronetics, Inc. (NASDAQ:STIM)

Landscape Capital Management L.L.C. purchased a new stake in shares of Neuronetics, Inc. (NASDAQ:STIM) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 69,263 shares of the company’s stock, valued at approximately $53,000. Landscape Capital Management L.L.C. owned approximately 0.23% of Neuronetics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. GSA Capital Partners LLP raised its position in shares of Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after acquiring an additional 30,837 shares in the last quarter. Gabelli Funds LLC raised its position in shares of Neuronetics by 88.2% during the 2nd quarter. Gabelli Funds LLC now owns 48,000 shares of the company’s stock valued at $86,000 after acquiring an additional 22,500 shares in the last quarter. First Eagle Investment Management LLC raised its position in shares of Neuronetics by 33.4% during the 2nd quarter. First Eagle Investment Management LLC now owns 1,039,009 shares of the company’s stock valued at $1,870,000 after acquiring an additional 260,000 shares in the last quarter. First Washington CORP raised its position in shares of Neuronetics by 88.8% during the 2nd quarter. First Washington CORP now owns 1,274,540 shares of the company’s stock valued at $2,294,000 after acquiring an additional 599,455 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Neuronetics by 124.5% during the 2nd quarter. Renaissance Technologies LLC now owns 322,200 shares of the company’s stock valued at $580,000 after acquiring an additional 178,700 shares in the last quarter. 53.59% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Neuronetics

In other Neuronetics news, Director Robert Cascella purchased 100,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $0.75 per share, with a total value of $75,000.00. Following the completion of the purchase, the director now owns 453,098 shares in the company, valued at $339,823.50. This trade represents a 28.32 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders acquired 137,776 shares of company stock valued at $105,860. 9.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on STIM shares. William Blair reissued a “market perform” rating on shares of Neuronetics in a research report on Monday, August 12th. Canaccord Genuity Group dropped their target price on Neuronetics from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Finally, JMP Securities dropped their target price on Neuronetics from $7.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 14th.

Neuronetics Price Performance

Shares of NASDAQ STIM opened at $0.97 on Tuesday. Neuronetics, Inc. has a 1-year low of $0.52 and a 1-year high of $5.07. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The business’s fifty day moving average price is $0.90 and its two-hundred day moving average price is $1.41. The firm has a market capitalization of $29.44 million, a PE ratio of -0.79 and a beta of 2.21.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.